MDxHealth (MDXH) EBITDA (2021 - 2026)

MDxHealth has disclosed EBITDA across 6 years of filings, most recently posting -$4.3 million for Q1 2026.

• EBITDA for Q1 2026 came in at -$4.3 million, down 226.0% year-over-year; the trailing twelve-month figure through Mar 2026 was -$4.1 million (up 63.9% YoY), and the FY2025 annual result was -$1.1 million, up 92.29% from the prior year.
• EBITDA came in at -$4.3 million for Q1 2026 at MDxHealth, down from -$2.1 million in the prior quarter.
• In the past five years, EBITDA ranged from a high of $17.5 billion in Q3 2022 to a low of -$17.5 billion in Q2 2022.
• The 5-year median for EBITDA is -$4.4 million (2023), against an average of -$5.4 million.
• Across the five-year window, EBITDA surged 127.82% in 2025 and plunged 226.0% in 2026, its largest moves.
• MDxHealth's EBITDA stood at -$8.9 million in 2022, then soared by 51.15% to -$4.4 million in 2023, then jumped by 68.47% to -$1.4 million in 2024, then tumbled by 53.27% to -$2.1 million in 2025, then tumbled by 105.45% to -$4.3 million in 2026.
• The last three EBITDA figures came in at -$4.3 million (Q1 2026), -$2.1 million (Q4 2025), and $952000.0 (Q3 2025), per Business Quant data.